USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - methyldopa 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. - methyldopa 1,5-water samenstelling overeenkomend met; methyldopa 0-water; - filmomhulde tablet - methyldopa (levorotatory)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. - methyldopa 1,5-water samenstelling overeenkomend met ; methyldopa 0-water - filmomhulde tablet - cellulose, microkristallijn (e 460) ; chinolinegeel aluminiumlak (e 104) ; citroenzuur 1-water (e 330) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; povidon k 25 (e 1201) ; siliciumdioxide (e 551) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; chinolinegeel aluminiumlak (e 104) ; citroenzuur 1-water (e 330) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; povidon k 25 (e 1201) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - methyldopa (levorotatory)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. - methyldopa 1,5-water samenstelling overeenkomend met; methyldopa 0-water; - filmomhulde tablet - methyldopa (levorotatory)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

centrafarm b.v. van de reijtstraat 31-e 4814 ne breda - methyldopa 1,5-water samenstelling overeenkomend met ; ; methyldopa 0-water 250 mg/stuk - tablet - cellulose, microkristallijn (e 460(i)) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), cellulose, microkristallijn (e 460) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), cellulose, microkristallijn (e 460) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), - methyldopa (levorotatory)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

centrafarm b.v. van de reijtstraat 31-e 4814 ne breda - methyldopa 1,5-water samenstelling overeenkomend met ; ; methyldopa 0-water 500 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), cellulose, microkristallijn (e 460) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), cellulose, microkristallijn (e 460) ; chinolinegeel (e 104) ; ethylcellulose (e 462) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; propyleenglycol (e 1520) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; zonnegeel fcf (e 110), - methyldopa (levorotatory)

USA - engelsk - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients:

USA - engelsk - NLM (National Library of Medicine)

mylan institutional inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 500 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

USA - engelsk - NLM (National Library of Medicine)

accord healthcare inc. - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 125 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - methyldopa (unii: 56lh93261y) (methyldopa anhydrous - unii:m4r0h12f6m) - methyldopa anhydrous 250 mg - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.